Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
This is now amazingly cheap. 50p target gets us a nice return. Just purchased a few today.
BOD is confident 201 will get done and that could be an instant 10 times current SP. New compounds to come, lab to generate big revenue and CLX.
I feel we are onto something big. The news today was a tiny set back.
Given you are the one constantly complaining then you should be providing the solutions other than simply stating replace BOD every day when you have no idea what you are talking about.
201 only has one hope and that is with TRX. As it has been stated by many including Suzy and Adam it is very hard to get a deal with old patents and low trial numbers. Why would a big pharma take 201 even for free if they have to risk losing money doing large trials. Suzy has stated they tend to take these types of drugs at phase 3.
The current strategy is perfect regarding SPV and university tie ups. It will return value with CLX and others once they come in. It is a low risk and low spend strategy.
You move in different directions. As I said it will take much longer and you would be starting from a lower SP so could be waiting 3 years before it hits 15-20p with new BOD. I don't see Adam wanting the job so I am not betting on that.
You will get your returns quicker with the current BOD and it will be more likely. If you don't like the current BOD then sell when you make your returns but enough said just common sense.
I disagree. Don't expect something better from someone else. It will take time to hire and for them to find themselves maybe 1 year. New BOD may not buy until at least 1 year has passed. We would drift and who knows who else leaves from the team. Build on what we have even though decisions at times have not been good. Unless you have 2 years to wait then fair play to you.
Fantastic post.
TheoremRx has built a broad portfolio of novel drugs targeting unmet medical needs in large market indications where it will advance each asset to partnering and licensing to global pharmaceutical companies. The US based company operates out of New York, NY and Montreal, Quebec.
Great points but really at 9 million market cap it's like a free investment given all the other products we have and likely 2/3 in SPV and more evaluations to come. We should be multiples higher even without 201.
Even if you conclude 50/50 with upside of a few 100% just for 201 then it's just amazing people need all this to seriously invest at these prices.
This was refreshing to read. Great post indicating 201 is on the way.
Murphy Canyon acquisition corp a NASDAQ listed company acquired a Cayman Islands registered company by the name of conduit pharmaceuticals limited
On 19/ 10/2021 a company by the name of conduit pharmaceuticals Inc was incorporated in Delaware
On 2/11/2021 (less than 2 weeks) valirx issued an RNA regarding TRX letter.
Both Murphy Canyon and TRX strategy is to take peptides and deprioritize compounds from other pharma to clinic.
Once the merger with Conduit completed Murphy Canyon will be delisted and the shareholders will become the owners of the new company and it will be listed on the Nasdaq, but Murphy Canyon requested from the shareholders to vote for a dealy of the listing and it was granted.
Today Valirx informed us that the deal was expected to be completed last year but there was a dealy
On 12/5/2023 Murphy Canyon issued Form S-4 signaling the starting process of the listing which is likely to take weeks rather than months.
I have strong feelings that TRX is just a cover used by Murphy Canyon/Conduit to go around shopping for compounds before the listing .
I am %75 confidence that the deal is happening with this company , the timing the similarities the location can not all be just coincidences, and I think Suzie will not be giving TRX all this time if she didn't see strong evidence the deal is happening, she knows her reputation and probably her job is on the line here.
As a result of all I decided to do 2 cheeky top ups today something I thought I will never do again,one at 9/17 for 43511 shares but it was shown as sell , the other one at 14/25 for 3198. And when I get home I will have a look under the sofa I am sure I have some money there.
Anyone willing and have the time to do more digging can start by going to Murphy canyon acquisition corp website.
AliRx achieved a major milestone in October 2022 with the formation of Cytolytix Limited, a majority owned subsidiary and SPV to aid the development of an exciting new technology to treat triple negative breast cancer. We believe this collaboration with Kings College London will serve as the model for future evolution of our collaborative development pipeline.
Two other projects with academics from Hokkaido and Barcelona University have also been in the evaluation phase throughout the year and, subject to a successful conclusion of our experiments, will also be incorporated into SPVs.
Nevertheless, successful evaluation of new science cannot be guaranteed and it remains important to build a risk balanced portfolio of projects to maintain a steady flow of new assets for further development.
To this end, we were very pleased to welcome Dr Cathy Tralau-Stewart to the team in September last year as interim CSO (now permanent). Cathy has brought a wealth of experience in assessing novel science, particularly from academic institutions, and has taken the lead in identifying, securing and developing a range of novel assets that help to manage development risks.
We were also delighted to have appointed Stella Panu as a new Board member. Stella has brought deep experience in both corporate finance and M&A and is helping the team to drive forward the tCRO® strategy, with the aim of generating near term income for ValiRx.
During 2022 it became clear that initiating the tCRO® through a buy-and-build strategy was going to be a significant challenge as the valuations of suitable acquisition candidates for a core laboratory facility, on which to build the tCRO®, were excessive and unlikely to create sufficient shareholder value. With Stella's guidance and Suzy's CRO expertise, the previous buy-and-build approach has been modified to focus on establishing our own core laboratory, incorporating the necessary technologies to support ValiRx's in-house pipeline and attract 3rd party business. We believe this will enable ValiRx to build the tCRO® with lower risk and lower cost, leading to more efficient use of capital.
Having successfully established the tCRO®, transferred our in-house projects and secured new customers, we will continue to seek opportunities to acquire capabilities and technologies that complement the overall vision of improving translational research and transition ValiRx into an income generating and profitable company.
Efforts continue to out-licence our clinical assets VAL201 and VAL401 but, disappointingly, we have not yet concluded out-licencing deals. The Letter of Intent with TheoremRx for VAL201 continues to be exclusive at this time as we still expect their funding efforts will progress to a conclusion, albeit more slowly than anticipated.
The shift of the tCRO® strategy towards a build-and-buy strategy and the delays to TheoremRx funding necessitated a placing in 2022,
201 deal officially on as per RNS today. Already delayed but will likely complete. If it does we move to 50-100p range if we have 2/3 in SPV which is likely this month. Cash for at least 12- 18 months minimum. Two SPV to announced this month.
We will be 25-30p when further cash is needed fairly confident of that.
Efforts continue to out-licence our clinical assets VAL201 and VAL401 but, disappointingly, we have not yet concluded out-licencing deals. The Letter of Intent with TheoremRx for VAL201 continues to be exclusive at this time as we still expect their funding efforts will progress to a conclusion, albeit more slowly than anticipated.